Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Dermatology Hospital of Southern Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
B7-H3 CAR-T cells are an investigational adoptive cellular immunotherapy consisting of autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B7-H3 (CD276) antigen. B7-H3 is a member of the B7 family of immune checkpoint proteins that is frequently overexpressed in various solid tumors, including malignant skin neoplasms, neuroblastoma, and gliomas, while showing limited expression in normal tissues. Upon binding to B7-H3 on the surface of tumor cells, the CAR-T cells undergo activation, proliferation, and secretion of cytotoxic cytokines, leading to the targeted destruction of B7-H3-expressing malignant cells. Early-phase clinical trials, such as those conducted by the Dermatology Hospital of Southern Medical University, are evaluating these cells for the treatment of B7-H3-positive malignant skin tumors and other advanced solid malignancies.
- Other names
- B7H3-CAR-T cellsB-7H3-CAR-T cellsB 7H3-CAR-T cellsCD276-targeted CAR-T cellsCD-276-targeted CAR-T cellsCD 276-targeted CAR-T cellsanti-B7-H3 CAR-Tanti-B-7-H3 CAR-Tanti-B 7-H3 CAR-T
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 CAR-T cells.